Cubist Pharmaceuticals Inc

Cubist Pharmaceuticals — Investor Presentation (May 2004)

13 slides from Cubist Pharmaceuticals's investor presentation, May 10, 2004

  1. Slide 1: Serious Infections. Serious Business.

  2. Slide 2: Cubicin Market Research

    Cubicin™ Market Research cuBist February 2004 + High awareness of Cubist — Second only to Pfizer as developer of agents for Gram-positive infections — Highest among emerging companies in antiinfectives + High awareness of Cubicin™ — Infectious Disease physicians at 95% — Hospital Pharmacists at 84%

  3. Slide 3: Increases in U.S. MRSA Rates

    Increases in U.S. MRSA Rates cuBIST 60 % pure F ra 40 3 ecu to! ase = i Senet [4 = 10 oo. =- 1 89 90 91 92 93 94 95 96 97 98 99 00 01 02 Sources: NNIS (CDC) and Purcell & Fergle, Texas AEM University, Presented at 2002 IDSA i

  4. Slide 4: U.S. Gram-positive Agents

    i U.S. Gram-positive Agents Growth of Vancomycin, Synercid & Zyvox Units (000) 48,000 , Annual Vancomycin . Growth 1999 - 2003: 14.6% 16,000 14,000 12,000 10,000 8,000 6,000 4,000, 2,000 17,228 1999 2000 2001 2002 2003 [ma Vancomycin IV m Synercid B Zyvox Total Source: IMS Health retail and non-reta

  5. Slide 5: Cubicin: U.S. Market Opportunity

    Cubicin™: U.S. Market Opportunity Addressing a Significant Patient Population CUBIST 18%) or proptyylactic use. ‘US Hospital All Courses Anti Staph” | Vancomycin | % of Vane Infections” 2003 2003 (2003 Use ‘Skin/Skin Structure 6063868 | 2,992,702 680,976 2% ‘Systemic infections 5408,620| 1,191,529 7

  6. Slide 6: Cubicin Penetration Paradigm

    Cubicin™ Penetration Paradigm cuBist Success Over Time aca Empiric Therapy; Full Experience gathering; Peer-to-Peer vancomycin replacement physician education/interaction; ST vancomycin failures a ww vancomycin failures Formulary Acceptance/Time

  7. Slide 7: Cubicin Label Expansion/Data Publication

    Cubicin™ Label Expansion/Data Publication aay + Label Expansion studies + Possible Phase 4 Research Studies — Phase 3 studyin endocarultisfbacteremia -»«— Use of Cubicirr™ in postsurgical wound — Osteomyelitis infections — Renal insufficiency — Line associated 8. aureus bacteremia — Febrile neutrope

  8. Slide 8: Formulary Trends

    oa Formulary Trends A&B Institutions as of 3/31/04 CUBIST A B Overall Restricted Acceptances 110) 140] 250! Unrestricted Acceptances 13) 26 39) Rejections * 7 6| 13) Total in Type 325) 550] 875 % Acceptance 95% 97%| 96%! 1% Unrestricted 11% 16%| _13%| % Having Met 40% 31%] 35% * All have ordered Cub

  9. Slide 9: Percent of Institutions Ordering

    Bee: 2 2 me ct of Institutions Ordering cuBIST As of 3/30/04 ee | 0 A B ¢ op ‘Some institutions have been re-classified since last data presentation. 9

  10. Slide 10: New Orders vs. Re-orders

    ™ Orders vs. Re-orders (60% reorders 58 % re-orders 54% re-orders 49% reorders End of Nov End of Dec End of Jan End of Feb. End of March, Doners m Reorders 10

  11. Slide 11: New vs. Repeat Accounts

    CUBIST Tea ORC] Repeat Accounts New vs. Repeat Accounts, 2004 (5 day rolling average) New vs. [Few Aestsiday = Repeat Accterday — Linear Repeat arcteidan) icin Cubi

  12. Slide 12: Comparison of IV Antibiotic Launches

    Comparison of IV Antibiotic Launches cuer) Comparison of Cumulative Sales ($000) from Launch (non-retail IMS data) tstmo 2ndmo 3rdmo sthmo Sthmo éthmo 7thmo shmo Sthmo 10thmo 11thmo 12thmo ——Cubicin = invanz_—--Synercid = ——ZywoxV— —-Rocephin — -*-Zosyn iF] Note: Cubicin™ data is from ICS; All other

  13. Slide 13: Searchable text section of graphics

    Searchable text section of graphics shown above [ GRA PHIC] Serious Infections. Serious Business. Statements made during this presentation that are not historicalfact may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors t

Cubist Pharmaceuticals — Investor Presentation (May 2004) on 6ix